Competitor teardown · 16 July 2026 · SmartStrongAlive

"BHRT Made Simple" by Sandi Krakowski

31 pages, 98.6MB, zero citations. Ten load-bearing claims checked against primary sources. Two survive. The two that don't survive worst are the two that could hurt somebody.

Gated on purpose. This page names a real person and calls specific claims of hers fabricated, with receipts. It is research for you, not a publication. Don't un-gate it, and don't reuse this framing in public copy: take the ground, not the fight.

The one-line read

This guide is emotionally excellent and evidentially bankrupt, and that gap is exactly the shape of your opening. She is better at naming the wound than you currently are. You are the only person in this niche who can name the wound and put a DOI next to it. Don't try to out-suffer her. Out-measure her.

What she does well, which you should take

Starting here on purpose. It converts, and dismissing it would cost you the useful half of this document. Everything below this heading is a compliment and a theft target.

She names the wound in the first paragraph

The hysterectomy at 31, then "you’re just getting older," then an antidepressant. By page 3 the reader has been seen. Your ICP doc says the identical thing in colder words: "their U.S. doctor said your labs are normal but they feel anything but normal." Same bruise.

The symptom-to-hormone table (p9)

Four rows, two columns, instant self-recognition. This is the highest-converting page in the document and it took her about 90 words. The reader finds herself in three of the four rows and concludes the guide understands her.

The doctor script (p16) and the walk-away red flags (p17)

Most menopause content stops at "advocate for yourself," which is not an instruction. She gives literal sentences to say out loud, then tells you how to read the response. "You are interviewing them for a job" is a genuinely good reframe.

The prep sheet (p25)

The best asset in the guide and the only page that leaves the PDF and enters an exam room. It’s buried on page 25 of 31, behind 24 pages of argument, and it isn’t even a fillable form. She built the one thing that matters and treated it as an appendix.

"What to IGNORE" (p18)

Subtractive advice is rare and it sticks. Telling a reader what to stop paying attention to is a trust move, because it costs the author something. The framing is worth taking even though three of her five items are wrong.

The fact-check

Every verdict verified 16 July 2026 against PubMed, FDA.gov, journal primary sources, and current position statements. Not from memory. Where she's directionally right, it says so.

The claim	Verdict	What's actually true
1"Just 30 minutes of weight training, three times a week, can lower your risk of dementia by a staggering 70%."	Fabricated	No study of any design reports this. A PubMed sweep for resistance training as exposure against incident dementia as outcome returns zero prospective cohorts. The number most likely leaked from Wanigatunga 2025 (JAMDA 26(2):105456, PMID 39826907), which found 69% lower dementia risk at 140+ min/week of accelerometer-measured moderate-to-vigorous activity. That is total physical activity, not lifting, observational, ~4 years of follow-up, and the authors themselves disclaim causality. Real numbers: resistance training improves executive-function scores in RCTs with modest effect sizes (Liu-Ambrose 2010, PMID 20101012); pooled physical activity gives RR ~0.80 for all-cause dementia (Blondell 2014).
2"According to the research, a staggering 94% of adults in America are metabolically unhealthy."	Misleading	Traceable to O’Hearn 2022 (JACC 80(2):138-151, PMID 35798448), which found 6.8% of US adults in optimal cardiometabolic health, so 93.2% not optimal, rounded up and stripped of attribution. Araujo 2019 (PMID 30484738) found 12.2% optimal, so 87.8%. Both use three tiers: optimal / intermediate / poor. Failing "optimal" on one component is not being metabolically ill, and O’Hearn’s definition counts anyone with prior cardiovascular disease against the 6.8% regardless of labs.
3"Women have 4–8x more testosterone than estrogen in their body before menopause, which directly affects their motivation, focus, and sex drive."	False, and this one is a gift	Rothman 2011 (Steroids 76(1-2):177-182, PMID 21070796) measured both hormones in the same samples by LC-MS/MS in 31 healthy premenopausal women. The real molar ratio is 1.65x to 2.19x, not 4-8x. To reach 4x, estradiol would have to sit at 36 pg/mL; to reach 8x, 18 pg/mL, which is postmenopausal. Skiba 2019 (PMID 31390028) puts median total T lower still at ~9.8 ng/dL. Rothman says plainly that LC-MS/MS values came in lower than legacy immunoassays. That is where "4-8x" comes from: pre-mass-spectrometry assays overestimated female testosterone, and the field never re-based the number. Separately, the framing is invalid regardless of the figure, because comparing raw serum concentrations of two hormones acting on different receptors is not endocrinology. On motivation and focus: Islam 2019 (Lancet Diab Endo 7(10):754-766, PMID 31353194), 36 RCTs and 8,480 participants, verbatim: "No effects of testosterone were reported for body composition, musculoskeletal variables, or cognitive measures." Only sex drive survives.
4BPC-157, the "Wolverine" peptide, "can help repair a damaged gut lining, soothe joint pain, and reduce systemic inflammation."	Zero human trials	PubMed today: 222 records for BPC-157, zero randomized controlled trials, zero clinical trials. Every promise in the guide rests on rodent data. It is not on the 503A Bulks List, has no USP monograph, is not FDA-approved, so it meets none of the three statutory conditions for legal compounding. FDA’s stated concern is immunogenicity risk and API characterization, with "no, or only limited, safety-related information." WADA prohibits it under S0 at all times, with no Therapeutic Use Exemption pathway. Watch this one: FDA’s Pharmacy Compounding Advisory Committee evaluates BPC-157 on 23-24 July 2026, one week out, for ulcerative colitis only. Not joints, not "systemic inflammation."
5"A single, deeply flawed study, the Women’s Health Initiative, terrified an entire generation of doctors." Later: "the old, debunked WHI study."	Misleading, and needlessly so	The WHI is not debunked. It was well conducted; what was wrong was generalizing from a cohort averaging 63.4 years old to symptomatic 50-year-olds. The honest version is stronger than the overreach. Chlebowski 2020 (JAMA 324(4):369-380, PMID 32721007), 20-year follow-up: estrogen alone REDUCED breast cancer incidence (HR 0.78, CI 0.65-0.93) and mortality (HR 0.60, CI 0.37-0.97). Estrogen plus a progestin raised incidence (HR 1.28). Manson 2017 (PMID 28898378): all-cause mortality HR 0.99. The Menopause Society’s 2022 position statement (PMID 35797481, still current, verified) finds the benefit-risk ratio favorable under 60 or within 10 years of menopause. And in November 2025 FDA removed the boxed warnings for cardiovascular disease, breast cancer, and dementia from menopausal hormone therapy, retaining only endometrial cancer for systemic estrogen-alone. That last one cuts against her: FDA relaxed warnings on FDA-approved hormone therapy, which is exactly the category compounded BHRT is not in.
6"Those prescriptions [antidepressants] quadrupled after the 2002 WHI study."	False	NCHS Data Brief 283: past-month antidepressant use went from 7.7% (1999-2002) to 12.7% (2011-2014). That is 65% over fifteen years, not 400%. Three further problems: the baseline period straddles 2002 so it cannot resolve a July-2002 discontinuity; the rise was already underway before WHI (Olfson and Marcus: 5.84% in 1996 to 10.12% in 2005); and NCHS states the increase was "similar among males and females." Men do not take menopausal hormone therapy. A WHI-driven mechanism would show a female-specific inflection. There isn’t one. The defensible adjacent claim is real though: HT prescribing fell 40-80% after 2002 and symptomatic women went looking for alternatives.
7"You need fat to absorb your hormones, especially if you are using transdermal patches or creams."	Backwards	Transdermal absorption is passive diffusion across the stratum corneum. It bypasses the gut entirely. There is no mechanism by which a meal reaches a patch. Checked against the actual FDA labels: the only occurrence of the word "food" in the entire Climara Pro transdermal label is "U.S. Food and Drug Administration." Meanwhile the food effect is real and label-documented for the routes she excludes: oral micronized progesterone ("Concomitant food ingestion increased the bioavailability"), and oral testosterone undecanoate ("Take JATENZO with food"), which is absorbed lymphatically via chylomicrons and genuinely needs dietary fat. She took a true fact about oral hormones and attached it, with an emphatic "especially," to the one route where it cannot operate.
8The guide never once distinguishes FDA-approved bioidentical hormones from COMPOUNDED bioidentical hormones.	The load-bearing omission	This is the defect everything else hangs on. "Bioidentical" is not the dividing line: estradiol patches, estradiol gels, and micronized progesterone are FDA-approved AND bioidentical, with trial evidence, potency assurance, and safety surveillance. Approved versus compounded is the real line; bioidentical versus synthetic is a marketing frame. NASEM’s FDA-commissioned 2020 review (doi:10.17226/25791) concluded there is "insufficient evidence to support the overall clinical utility of cBHT" and recommended restricting it to documented allergy or documented need for an unavailable dosage form, adding that "patient preference alone should not determine the use of cBHT preparations." A lead magnet promoting compounded BHRT to a general audience of women 45-65 is precisely the patient-preference channel NASEM said should not drive prescribing.
9"I put all of the diseases into remission" (RA, Crohn’s, Addison’s, SLE Lupus, Hashimoto’s) through hormonal restoration.	Dangerous	Addison’s disease is autoimmune destruction of the adrenal cortex. The cortex does not regenerate, so cortisol cannot be "restored" by supporting adrenals that no longer exist. There is no remission, and no BHRT pathway to one. Standard of care is lifelong glucocorticoid plus fludrocortisone replacement (Endocrine Society guideline, PMID 26760044). Adrenal crisis runs ~8 per 100 patient-years and the listed precipitants include, verbatim, "forgetting or discontinuing glucocorticoid therapy" (PMID 31223468); it occurs in about half of patients after diagnosis and is fatal untreated (Lancet, PMID 33484633). The likely confusion is real remission in glucocorticoid-induced (tertiary) adrenal insufficiency, where the HPA axis recovers after a taper. Different condition, different mechanism. If one reader with Addison’s stops her hydrocortisone because of this page, the plausible outcome is death.
10Creatine "helps plump the skin by drawing water into your cells" and helps "clear brain fog and improve executive function."	Half wrong, and she picked the null half	Skin: no evidence. Creatine draws water into skeletal muscle via the CreaT transporter; skin has minimal CreaT expression and is not a creatine-storage tissue. The only adjacent literature is topical creatine in cosmetics, which is a different route and industry-affiliated. Cognition: Xu 2024 (Front Nutr 11:1424972, PMID 39070254), 16 RCTs, found memory SMD 0.31 at moderate GRADE certainty, and verbatim "no significant improvements were found on overall cognitive function or executive function." So she named executive function, the one domain that is null, and skipped memory, the one with support. Effects were larger in females, which is the finding she’d have wanted.

Four patterns run through the failures:

Real finding, inflated number. Claims 1, 2 and 6 each sit on a genuine literature and then attach a figure that doesn't appear in it. She didn't need to. The real numbers were good enough to make her point.
Legacy-assay folklore. Claim 3's "4-8x" descends from pre-mass-spectrometry immunoassays that overestimated female testosterone. The field has never re-based it. Hold that thought.
Rodent data sold as clinical fact. Claim 4 makes three specific clinical promises with zero human RCTs behind them.
Where she's right, the honest version is stronger. Estrogen alone reduced breast cancer incidence and mortality. Hormone therapy doesn't raise all-cause mortality. FDA pulled the boxed warnings in November 2025. None of that needs the word "debunked," and reaching for it puts a citable case at the mercy of an uncitable adjective.

The two that aren't rigor problems

Claims 9 and 4 are different in kind from the rest. They aren't sloppy, they're hazardous, and they're the reason this teardown stays gated rather than becoming a post.

Addison's "remission"

A reader with Addison's who believes hormonal restoration can put it into remission, and stops her hydrocortisone, can die of adrenal crisis. That's not a rhetorical flourish: discontinuing glucocorticoids is a named precipitant in the literature, crisis hits roughly half of patients after diagnosis, and it's fatal untreated. This claim sits in an About-the-Author box, which is the softest, least-scrutinized part of any document.

BPC-157

Promoted by name, with clinical promises, to a general audience of women, with no mention that it has zero human randomized trials, no approval anywhere, no legal compounding route, and a WADA all-times ban. FDA's advisory committee looks at it on 23-24 July, one week from now, for ulcerative colitis only. Whatever they decide, none of it will be about joints.

Neither of these is a reason to attack her publicly. They're a reason to be certain your own guide has a real disclaimer and no unapproved compounds in it.

It also can't be delivered, which is almost funny

Set the science aside. This file has problems a proofreader would catch.

98.6MB. Two decorative images are 34.6MB and 35.0MB, saved as PNG at 3584×4800 when they're photographs. That's 70MB of the 98.6. The file exceeds Gmail's 25MB attachment cap, so it can't be emailed, and it's punishing to open on a phone. It should be 3-5MB. This is a conversion bug wearing a design costume.
The action plan can't count. Step 2 is labeled "4." Steps 3 and 4 have no number at all. On the page that tells the reader what to do next.
The cover collides with itself. The title renders twice: once as giant ghosted letters baked into the background image, once as live text on top of them. "BY SANDI KRAKOWSKI" appears in the artwork and is partially covered by the real byline.
Page 30 is a wordless 35MB image whose banner reads "WOMENS HEALTH COLLECTIVE." Missing apostrophe, and a brand name that matches nothing else in the funnel, where it's "Women's Health Mentorship" throughout.
The page count is padded. Half-empty pages throughout; several end at two-thirds height. 31 pages of 18 pages of content.
No medical disclaimer anywhere in 31 pages that recommend specific doses, name a non-approved peptide, and carry health-outcome testimonials attributed to "Anonymous Member."

The funnel argues against its own product

This is the strategic crack, and it's wider than any single wrong number. The guide spends twenty pages establishing that individualization is everything, that cookie-cutter telehealth protocols are "not just ineffective, they can be dangerous," and that you must find a practitioner who tests comprehensively and listens.

Then it sells a $247/month community and an AI bot. And the testimonial it leads with is: I asked your AI about my hormone issues at 2am when I couldn't sleep. I got more helpful answers in 10 minutes than I got from my doctor in 3 visits.

That testimonial sells precisely the thing the guide spent twenty pages warning against. The product does not deliver the thing the argument says you need, and a reader who actually follows the guide's advice has no reason to buy the guide's offer.

It gets better for you. Your own ICP doc lists, under turn-offs: anything that requires a $4k functional-medicine doctor. Her "Mercedes Benz level of care" is that, named and celebrated. And the "Mercedes Benz" road leads somewhere specific: Jiang 2021 (Menopause 28(8):867-874, PMID 33973545) compared 384 pellet patients against 155 on FDA-approved therapy. Any side effect: 57.6% versus 14.8%, odds ratio 8.0. Hysterectomy: 20.3% versus 6.3%. Mean peak testosterone 194 ng/dL against a normal premenopausal 15-23. One in five pellet patients had a hysterectomy.

So the guide's own logic, followed honestly, lands the reader on FDA-approved transdermal estradiol and micronized progesterone from an ordinary competent clinician. Which is roughly what you'd tell her, for free.

The opening

You can't out-biography her. You can out-measure her.

Be honest about this first: hysterectomy at 31, five autoimmune diagnoses, 185 to 130, hip thrusting 385 at 61. That's a more dramatic story than yours, and competing on transformation intensity is a game you lose. Her authority claim is biographical, which is why the zero citations cost her nothing with her audience.

Your ground is the thing she structurally cannot touch. You're a medical technologist. You know what happens to the tube.

Your ICP's defining wound, in your own words, is: their U.S. doctor said your labs are normal but they feel anything but normal. Sandi's answer to that is "your doctor is dismissive, join my community." Your answer can be: your labs may not be normal. They may be wrong. Here's how to tell.

That's true, it's useful, it's citable, and it's unoccupied. Your own June whitespace re-run explicitly refuted "Menopause Taylor owns labs." Nobody has this ground.

And the fact-check handed you the proof unprompted. Claim 3's "4-8x testosterone" is wrong because of an assay artifact. Rothman 2011 measured both hormones in the same samples by LC-MS/MS and got 1.65-2.19x, and stated directly that the mass-spec values came in lower than legacy immunoassays. The entire BHRT influencer field is quoting a number generated by an assay that overestimated female testosterone, and not one of them knows that's why. You would have caught it from the bench.

Which means the assay trap isn't a clever content angle. It's a real, documented, ongoing failure with names attached:

Total testosterone by immunoassay is unreliable at female concentrations. The platforms were validated on male ranges. A woman gets a number, gets told it's normal, and the number is noise. LC-MS/MS is the reference method and she has to ask for it by name.
Free testosterone without SHBG is uninterpretable. SHBG is absent from Sandi's "comprehensive" panel. It binds testosterone with roughly three times the affinity it binds estradiol, so the free-fraction ratio isn't the total ratio. You cannot calculate free T without it.
Estradiol at postmenopausal levels needs a sensitive assay. Standard E2 immunoassays lose accuracy exactly where these women live.
Reference ranges are population ranges. Built from a population containing a great many untreated symptomatic women. "Normal" means "common around here." It has never meant "optimal for you."
Timing. Progesterone drawn on the wrong cycle day is uninterpretable, and the guide gives no timing guidance at all.

Every one of those is a moment where a woman is told she's fine and isn't, and every one is invisible to everybody else in this space. That's the magnet.

The build: the SmartStrongAlive counter-magnet

Working title to fight about later: "Your Labs Are 'Normal.' You Are Not Imagining This." It sits one inch from the locked tagline, which is the point.

The structural move is an inversion. Sandi runs 24 pages of argument, then one page of tool, then six pages of sell. Lead with the instrument. The argument becomes annotation on the instrument, and the sell is one quiet line at the end. Target 12-16 dense pages, not 31 padded ones.

01One page: the wound, and the reframe

Your story, first person, short. Then the turn: "normal" is a population range built from a population full of untreated symptomatic women, and it is not your range. And sometimes the number itself is wrong. That second sentence is the whole magnet.

02The Panel

Every marker: what it is, why it matters, which assay to demand, when in the cycle to draw it, and what the number can and cannot tell you. Her panel is missing SHBG entirely, which makes free testosterone uninterpretable. It includes reverse T3, which is a functional-medicine shibboleth. It says "APOa and APOb," which is sloppy enough to be ambiguous between apolipoprotein A-I and Lp(a), two completely different analytes. It has no FSH, no ferritin (while recommending red meat for iron), and no baseline CBC or CMP before starting therapy. You can fix all of that from memory. Nobody else in the niche can.

03The Assay Trap

The section only you can write, and the reason to build this at all. See below.

04The Script

Hers is good. Yours is better because it is specific. "I would like total testosterone by LC-MS/MS, not immunoassay" is a sentence that changes what physically happens to the tube. "Are you willing to work with me" is a sentence that changes nothing.

05What we actually do not know

The calibration section, and the one Sandi structurally cannot write. Testosterone for energy and focus: no RCT support (Islam 2019). Testosterone for mood: uncertain, and say so even though it is your own story. Long-term outcome data on testosterone in women: thin. Naming the edges of the evidence is the highest-trust move available and it costs nothing, because you are not selling certainty.

06The fillable kit

Real PDF form fields, not print-only lines. Symptom log, the panel as a checklist she hands across the desk, and a results tracker with space for the assay method next to each value. Hers is a picture of a worksheet. Yours should be a tool.

07Citations, every claim, DOI-linked

You have 20,932 sources in Zotero and retraction checking wired up. She has zero citations in 31 pages. This is free ground and it is the only ground she cannot take back.

08Disclaimer, done properly, and a quiet CTA

She has no medical disclaimer anywhere in 31 pages while recommending specific doses of a non-FDA-approved peptide. You are a medical technologist sharing your own story and research, not giving medical advice. Then one quiet line to the Substack at the end. No early CTA.

Head to head

	BHRT Made Simple	SmartStrongAlive
Authority rests on	Biography	Biography + credential + citation
Core promise	"You're not crazy"	"You're not crazy, and here's the number that proves it"
The tool	Print worksheet, page 25 of 31	Fillable panel + tracker, front of the book
Citations	Zero	Every claim, DOI-linked
Uncertainty	None admitted	Named in its own section
On compounded BHRT	Silent	The distinction that matters
File	98.6MB, unemailable	Under 5MB
The ask	$247/month	Free Substack

What I'd watch, honestly

The real risk is producing something correct and inert

Sandi converts on rage and certainty. Citations don't convert. If the counter to her is "same content but with footnotes," you'll ship something accurate that nobody finishes. The instruction is not "citations instead of emotion." It's the same anger, aimed properly. Keep the fire, fix the facts. Your tagline already does this and it's the best sentence either of you has.

Certainty versus calibration is a real trade, not a free win

She sells certainty because a $247/month community needs it. You can sell calibration because a free Substack doesn't. Calibration is more durable, since you can never be caught out on a fabricated number, but it's a slower build. Go in knowing that.

The palettes are close enough to notice

Her guide is deep green and gold. Vital Teal is deep teal and gold. Dark serif cover, gold accent, same genre. Distinguishable side by side, but don't put a dark-green-and-gold hormone PDF into this niche without looking at hers first.

You may already have a lead magnet

coaching/funnel/ specs a "7-Day Perimenopause & Menopause Brain Fog Reset" feeding the $47-97 protocol. That's a different funnel for a different product, but I'm not building a second magnet in parallel without you saying which one is live. Your call, and it's a real question, not a formality.

Unrelated, but I found it on the way in

28 of 353 hub pages have no password gate, including the most recent one (menopause-anhedonia-language, which quotes real women's comments). PersonalLayout doesn't gate globally, so it's per-page and the newest pages are missing it. Might be deliberate. If it isn't, it's worth an hour.

What I'd do next

You pick the magnet. Lab panel for the Substack, or the Brain Fog Reset for the coaching ladder. I'm not guessing between them.
Harvest before searching. The ResearchLibrary already holds most of what the panel section needs. Check status: on every note before citing; index and abstract aren't citable.
Draft the Assay Trap section first. If that section isn't genuinely surprising, the whole thesis is wrong and better to know at 1,200 words than 12 pages.
Then the panel, then the script, then the fillable kit. Typst for the PDF, per the standing rule. Keep it under 5MB, which is trivial if nothing is a 3584×4800 PNG.

Private Hub